Related Experiment Video
Updated: May 22, 2026
10:20
Method for Identifying Small Molecule Inhibitors of the Protein-protein Interaction Between HCN1 and TRIP8b
Published on: November 11, 2016
Integrated Virtual Screening Approaches to Identify Novel N- Substituted Heterocyclic Compounds as MAPK Inhibitors
Aravind Kanniappan1, Annapoorna Vadivelu1
1Department of Pharmaceutical Chemistry, College of Pharmacy, Mother Theresa Post Graduate and Research Institute of Health Sciences, Gorimedu, Puducherry-605006, India.
Summary
This study identifies novel heterocyclic compounds as potential inhibitors for the Mitogen-Activated Protein Kinase (MAPK) pathway, crucial in neuroinflammation and drug resistance. Promising candidates with favorable pharmacokinetic profiles were discovered, offering new therapeutic avenues.
Area of Science:
- Medicinal Chemistry
- Computational Drug Discovery
- Neuroscience
Background:
- Mitogen-Activated Protein Kinase (MAPK) signaling is implicated in neurodegenerative diseases and drug resistance.
- Targeting MAPK pathways offers a strategy to combat neuroinflammation.
Purpose of the Study:
- To identify novel N-substituted heterocyclic compounds as inhibitors of MAPK (p38, ERK, JNK).
- To evaluate these compounds using in silico molecular docking and ADMET profiling for neuroinflammation treatment.
Main Methods:
- Designed and docked 135 nitrogen-substituted heterocyclic derivatives against MAPK targets (PDB: 3LN1).
- Evaluated binding interactions and compared scores with Trametinib.
- Assessed ADMET properties of selected compounds using Swiss ADME, Molinspiration, OSIRIS, and Protox II.
Main Results:
- Over 6% of designed compounds showed good binding scores against MAPK targets.
- A maximum binding score of -8 kcal/mol was achieved for P38-alpha MAP kinase (2BAL).
- 13 compounds exhibited favorable pharmacokinetic and pharmacodynamic profiles after ADMET screening.
Conclusions:
- Identified 8 molecules as promising, synthesizable inhibitors of P38-alpha MAP kinase.
- The screened compounds demonstrate potential for developing new drugs targeting the MAPK pathway in neuroinflammation.
